Drug Trial Radar · NCT07389278
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
97
Planned (sponsor's estimate)
Start
Jun 1, 2027
Primary completion
Jun 30, 2032
Study completion Jun 30, 2035
Sponsor
- Lead sponsor
- Sabine Mueller, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
Conditions
- Glioblastoma
- High-Grade Glioma (WHO III-IV)
- High-grade Glioma
- Diffuse Midline Glioma, H3 K27M-Mutant
- Diffuse Hemispheric Glioma, H3G34 Mutant
Interventions
ADI-PEG 20 (Arginine deiminase pegylated)Drug
Given intramuscularly (IM)
Temozolomide (TMZ)Drug
Given orally (PO)
Standard of Care Radiation Therapy (RT)Radiation
Undergo RT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with Treatment-emergent Adverse Events (TrAE) (Phase 1)Time frame: Up to 104 weeks
- Progression-Free Survival (PFS) for HGG histone-WT (Phase 2, Cohort 1)Time frame: Up to 12 months
- Progression-Free Survival (PFS) for H3K27 altered diffuse midline glioma (DMG) (Phase 2, Cohort 2)Time frame: Up to 12 months
- Progression-Free Survival (PFS) for H3G34 mutant diffuse hemispheric glioma (DHG) (Phase 2, Cohort 3)Time frame: Up to 10 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.